FDA Grants Fast Track Designation to Tipifarnib to Treat Lymphoma

Kura Oncology ’s leading drug candidate, tipifarnib, was granted fast track designation by the FDA to treat adults of T-cell lymphomas.

Source: CancerNetwork - March 3, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news